{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T18:07:41Z","timestamp":1779905261607,"version":"3.53.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010564","name":"Deutsches Zentrum f\u00fcr Lungenforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010564","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medizinische Fakult\u00e4t Heidelberg der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To explore the prognostic value of serial dynamic contrast-enhanced (DCE) MRI in patients with advanced pulmonary adenocarcinoma undergoing first-line therapy with either tyrosine-kinase inhibitors (TKI) or platinum-based chemotherapy (PBC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients underwent baseline (day 0, n\u2009=\u200998), and post-therapeutic DCE MRI (PBC: day\u2009+\u20091, n\u2009=\u200952); TKI: day\u2009+\u20097, n\u2009=\u200946) at 1.5T. Perfusion curves were acquired at 10, 40, and 70 s after contrast application and analysed semiquantitatively. Treatment response was evaluated at 6 weeks by CT (RECIST 1.1); progression-free survival (PFS) and overall survival\u00a0 were analysed with respect to clinical and perfusion parameters. Relative uptake was defined as signal difference between contrast and non-contrast images, divided by the non-contrast signal. Predictors of survival were selected using Cox regression analysis. Median follow-up was 825 days.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In pre-therapeutic and early post-therapeutic MRI, treatment responders (n\u2009=\u200927) showed significantly higher relative contrast uptake within the tumor at 70 s  after application as compared to non-responders (n\u2009=\u200971, p\u2009\u2264\u20090.02), response defined as PR by RECIST 1.1 at 6 weeks. There was no significant change of perfusion at early MRI after treatment. In multivariate regression analysis of selected parameters, the strongest association with PFS were relative uptake at 40 s in the early post-treatment MRI and pre-treatment clinical data (presence of liver metastases, ECOG performance status).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Higher contrast uptake within the tumor at pre-treatment and early post-treatment MRI was associated with treatment response and better prognosis. DCE MRI of pulmonary adenocarcinoma may provide important prognostic information.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12880-022-00943-x","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:03:30Z","timestamp":1670249010000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Dynamic contrast enhanced MRI of pulmonary adenocarcinomas for early risk stratification: higher contrast uptake associated with response and better prognosis"],"prefix":"10.1186","volume":"22","author":[{"given":"Stephan","family":"Rheinheimer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Christopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Erdmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Saupe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Golpon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Vogel-Claussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Dinkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus Peter","family":"Heussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Ulrich","family":"Kauczor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudula","family":"Heussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,5]]},"reference":[{"issue":"33","key":"943_CR1","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.18632\/oncotarget.26886","volume":"10","author":"P Christopoulos","year":"2019","unstructured":"Christopoulos P, Budczies J, Kirchner M, Dietz S, Sultmann H, Thomas M, et al. Defining molecular risk in ALK(+) NSCLC. Oncotarget. 2019;10(33):3093\u2013103.","journal-title":"Oncotarget."},{"key":"943_CR2","doi-asserted-by":"publisher","first-page":"152125","DOI":"10.4061\/2011\/152125","volume":"2011","author":"S Abbasi","year":"2011","unstructured":"Abbasi S, Badheeb A. Prognostic factors in advanced non-small-cell lung cancer patients: patient characteristics and type of chemotherapy. Lung Cancer Int. 2011;2011:152125.","journal-title":"Lung Cancer Int"},{"issue":"1","key":"943_CR3","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s12885-020-06738-z","volume":"30","author":"F Hardtstock","year":"2020","unstructured":"Hardtstock F, Myers D, Li T, Cizova D, Maywald U, Wilke T, et al. Real-world treatment and survival of patients with advanced non-small cell lung cancer: a german retrospective data analysis. BMC Cancer. 2020;30(1):260.","journal-title":"BMC Cancer"},{"issue":"1","key":"943_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2967\/jnumed.110.078261","volume":"52","author":"AJ de Langen","year":"2011","unstructured":"de Langen AJ, van den Boogaart V, Lubberink M, Backes WH, Marcus JT, van Tinteren H, et al. Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI. J Nucl Med. 2011;52(1):48\u201355.","journal-title":"J Nucl Med"},{"issue":"8","key":"943_CR5","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/cncr.22979","volume":"110","author":"LF de Geus-Oei","year":"2007","unstructured":"de Geus-Oei LF, van der Heijden HF, Corstens FH, Oyen WJ. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer. 2007;110(8):1654\u201364.","journal-title":"Cancer."},{"issue":"7","key":"943_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.crad.2018.02.013","volume":"73","author":"J Xu","year":"2018","unstructured":"Xu J, Mei L, Liu L, Wang K, Zhou Z, Zheng J. Early assessment of response to chemotherapy in lung cancer using dynamic contrast-enhanced MRI: a proof-of-concept study. Clin Radiol. 2018;73(7):625\u201331.","journal-title":"Clin Radiol"},{"issue":"20","key":"943_CR7","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-07-4310","volume":"14","author":"ML Ah-See","year":"2008","unstructured":"Ah-See ML, Makris A, Taylor NJ, Harrison M, Richman PI, Burcombe RJ, et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res. 2008;14(20):6580\u20139.","journal-title":"Clin Cancer Res."},{"issue":"2","key":"943_CR8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/jmri.23660","volume":"36","author":"YC Chang","year":"2012","unstructured":"Chang YC, Yu CJ, Chen CM, Hu FC, Hsu HH, Tseng WY, et al. Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin. J Magn Reson Imaging. 2012;36(2):387\u201396.","journal-title":"J Magn Reson Imaging"},{"issue":"8","key":"943_CR9","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s00330-011-2102-x","volume":"21","author":"T Chikui","year":"2011","unstructured":"Chikui T, Kawano S, Kawazu T, Hatakenaka M, Koga S, Ohga M, et al. Prediction and monitoring of the response to chemoradiotherapy in oral squamous cell carcinomas using a pharmacokinetic analysis based on the dynamic contrast-enhanced MR imaging findings. Eur Radiol. 2011;21(8):1699\u2013708.","journal-title":"Eur Radiol"},{"issue":"11","key":"943_CR10","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1007\/s00330-016-4276-8","volume":"26","author":"SH Ng","year":"2016","unstructured":"Ng SH, Liao CT, Lin CY, Chan SC, Lin YC, Yen TC, et al. Dynamic contrast-enhanced MRI, diffusion-weighted MRI and (18)F-FDG PET\/CT for the prediction of survival in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation. Eur Radiol. 2016;26(11):4162\u201372.","journal-title":"Eur Radiol"},{"issue":"8","key":"943_CR11","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.mri.2014.05.009","volume":"32","author":"JJ Park","year":"2014","unstructured":"Park JJ, Kim CK, Park SY, Simonetti AW, Kim E, Park BK, et al. Assessment of early response to concurrent chemoradiotherapy in cervical cancer: value of diffusion-weighted and dynamic contrast-enhanced MR imaging. Magn Reson Imaging. 2014;32(8):993\u20131000.","journal-title":"Magn Reson Imaging"},{"issue":"1","key":"943_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/diagnostics9010035","volume":"9","author":"NH Langer","year":"2019","unstructured":"Langer NH, Langer SW, Johannesen HH, Hansen AE, Costa J, Klausen TL, et al. Very early response evaluation by PET\/MR in patients with lung cancer-timing and feasibility. Diagnostics (Basel). 2019;9(1):35.","journal-title":"Diagnostics (Basel)."},{"issue":"4","key":"943_CR13","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/1754-9485.12086","volume":"57","author":"ME Trinkaus","year":"2013","unstructured":"Trinkaus ME, Blum R, Rischin D, Callahan J, Bressel M, Segard T, et al. Imaging of hypoxia with 18F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy. J Med Imaging Radiat Oncol. 2013;57(4):475\u201381.","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"5","key":"943_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11864-016-0399-z","volume":"17","author":"G Thanarajasingam","year":"2016","unstructured":"Thanarajasingam G, Bennani-Baiti N, Thompson CA. PET-CT in staging, response evaluation, and surveillance of lymphoma. Curr Treat Options Oncol. 2016;17(5):24.","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"943_CR15","doi-asserted-by":"publisher","first-page":"10352","DOI":"10.1038\/s41598-017-09678-0","volume":"4","author":"A Sadeghi-Naini","year":"2017","unstructured":"Sadeghi-Naini A, Sannachi L, Tadayyon H, Tran WT, Slodkowska E, Trudeau M, et al. Chemotherapy-response monitoring of breast Cancer patients using quantitative ultrasound-based intra-tumour Heterogeneities. Sci Rep. 2017;4(1):10352.","journal-title":"Sci Rep"},{"issue":"6","key":"943_CR16","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2214\/AJR.16.17242","volume":"209","author":"MA Lee","year":"2017","unstructured":"Lee MA, Cho SH, Seo AN, Kim HJ, Shin KM, Kim SH, et al. Modified 3-point MRI-based tumor regression grade incorporating DWI for locally advanced rectal Cancer. AJR Am J Roentgenol. 2017;209(6):1247\u201355.","journal-title":"AJR Am J Roentgenol"},{"issue":"8","key":"943_CR17","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1007\/s00330-020-06768-y","volume":"30","author":"X Wang","year":"2020","unstructured":"Wang X, Wan Q, Chen H, Li Y, Li X. Classification of pulmonary lesion based on multiparametric MRI: utility of radiomics and comparison of machine learning methods. Eur Radiol. 2020;30(8):4595\u2013605.","journal-title":"Eur Radiol"},{"key":"943_CR18","first-page":"135841","volume":"2014","author":"J Yu","year":"2014","unstructured":"Yu J, Li W, Zhang Z, Yu T, Li D. Prediction of early response to chemotherapy in lung cancer by using diffusion-weighted MR imaging. Sci World J. 2014;2014:135841.","journal-title":"ScientificWorldJournal"},{"key":"943_CR19","doi-asserted-by":"publisher","first-page":"35569","DOI":"10.1038\/srep35569","volume":"20","author":"X Tao","year":"2016","unstructured":"Tao X, Wang L, Hui Z, Liu L, Ye F, Song Y, et al. DCE-MRI perfusion and permeability parameters as predictors of tumor response to CCRT in patients with locally advanced NSCLC. Sci Rep. 2016;20:6:35569.","journal-title":"Sci Rep"},{"issue":"4","key":"943_CR20","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.ijrobp.2018.02.031","volume":"102","author":"SH Lee","year":"2018","unstructured":"Lee SH, Rimner A, Gelb E, Deasy JO, Hunt MA, Humm JL, et al. Correlation between tumor metabolism and semiquantitative perfusion magnetic resonance Imaging Metrics in non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2018;102(4):718\u201326.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"2","key":"943_CR21","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.21037\/apm-19-622","volume":"10","author":"JH Kim","year":"2021","unstructured":"Kim JH, Lee JW, Park K, Ahn MJ, Moon JW, Ham SY, et al. Dynamic contrast-enhanced MRI for response evaluation of non-small cell lung cancer in therapy with epidermal growth factor receptor tyrosine kinase inhibitors: a pilot study. Ann Palliat Med. 2021;10(2):1589\u201398.","journal-title":"Ann Palliat Med"},{"issue":"1","key":"943_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13244-019-0764-0","volume":"10","author":"NM deSouza","year":"2019","unstructured":"deSouza NM, Achten E, Alberich-Bayarri A, Bamberg F, Boellaard R, Clement O, et al. Validated imaging biomarkers as decision-making tools in clinical trials and routine practice: current status and recommendations from the EIBALL* subcommittee of the European Society of Radiology (ESR). Insights Imaging. 2019;10(1):87.","journal-title":"Insights Imaging."},{"issue":"1","key":"943_CR23","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/bcr2815","volume":"23","author":"EA O\u2019Flynn","year":"2011","unstructured":"O\u2019Flynn EA, DeSouza NM. Functional magnetic resonance: biomarkers of response in breast cancer. Breast Cancer Res. 2011;23(1):204.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"943_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.bjc.6603515","volume":"29","author":"JP O\u2019Connor","year":"2007","unstructured":"O\u2019Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer. 2007;29(2):189\u201395.","journal-title":"Br J Cancer"},{"key":"943_CR25","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Litiere S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132\u20137.","journal-title":"Eur J Cancer"},{"issue":"1","key":"943_CR26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ejrad.2014.10.007","volume":"84","author":"M Koenigkam-Santos","year":"2015","unstructured":"Koenigkam-Santos M, Optazaite E, Sommer G, Safi S, Heussel CP, Kauczor HU, et al. Contrast-enhanced magnetic resonance imaging of pulmonary lesions: description of a technique aiming clinical practice. Eur J Radiol. 2015;84(1):185\u201392.","journal-title":"Eur J Radiol"},{"issue":"4","key":"943_CR27","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/1740774515586176","volume":"12","author":"RA Betensky","year":"2015","unstructured":"Betensky RA. Measures of follow-up in time-to-event studies: why provide them and what should they be? Clin trials. 2015;12(4):403\u20138.","journal-title":"Clin trials."},{"issue":"4","key":"943_CR28","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343\u20136.","journal-title":"Control Clin Trials"},{"issue":"8","key":"943_CR29","doi-asserted-by":"publisher","first-page":"e1007230","DOI":"10.1371\/journal.pcbi.1007230","volume":"15","author":"M Gabel","year":"2019","unstructured":"Gabel M, Hohl T, Imle A, Fackler OT, Graw F. FAMoS: a flexible and dynamic algorithm for Model Selection to analyse complex systems dynamics. PLoS Comput Biol. 2019;15(8):e1007230.","journal-title":"PLoS Comput Biol"},{"key":"943_CR30","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna (2020). https:\/\/www.R-project.org."},{"issue":"4","key":"943_CR31","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.2214\/AJR.08.1367","volume":"193","author":"J Wang","year":"2009","unstructured":"Wang J, Wu N, Cham MD, Song Y. Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. AJR Am J Roentgenol. 2009;193(4):1090\u20136.","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"943_CR32","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1148\/radiol.11100600","volume":"259","author":"F Fraioli","year":"2011","unstructured":"Fraioli F, Anzidei M, Zaccagna F, Mennini ML, Serra G, Gori B, et al. Whole-tumor perfusion CT in patients with advanced lung adenocarcinoma treated with conventional and antiangiogenetic chemotherapy: initial experience. Radiology. 2011;259(2):574\u201382.","journal-title":"Radiology"},{"issue":"3","key":"943_CR33","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/jmri.21060","volume":"26","author":"HJ Yu","year":"2007","unstructured":"Yu HJ, Chen JH, Mehta RS, Nalcioglu O, Su MY. MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy. J Magn Reson Imaging. 2007;26(3):615\u201323.","journal-title":"J Magn Reson Imaging"},{"issue":"1029","key":"943_CR34","doi-asserted-by":"publisher","first-page":"20120174","DOI":"10.1259\/bjr.20120174","volume":"86","author":"F Fraioli","year":"2013","unstructured":"Fraioli F, Anzidei M, Serra G, Liberali S, Fiorelli A, Zaccagna F, et al. Whole-tumour CT-perfusion of unresectable lung cancer for the monitoring of anti-angiogenetic chemotherapy effects. Br J Radiol. 2013;86(1029):20120174.","journal-title":"Br J Radiol"},{"issue":"8","key":"943_CR35","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1007\/s00330-013-2821-2","volume":"23","author":"N Tacelli","year":"2013","unstructured":"Tacelli N, Santangelo T, Scherpereel A, Duhamel A, Deken V, Klotz E, et al. Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy. Eur Radiol. 2013;23(8):2127\u201336.","journal-title":"Eur Radiol"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-022-00943-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-022-00943-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-022-00943-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:06:15Z","timestamp":1670249175000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-022-00943-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,5]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["943"],"URL":"https:\/\/doi.org\/10.1186\/s12880-022-00943-x","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,5]]},"assertion":[{"value":"23 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committee of the medical faculty of Heidelberg (S-445\/2015), the written informed consent of all patients was waived, and the whole study was performed by the World Medical Association guidelines and Declaration of Helsinki, revised in 2000 in Edinburgh. All patient data were analyzed anonymously.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"215"}}